Tiziana buys bio-repository from Shardna to study Sardinia's thriving older population

18 July 2016

UK biotech Tiziana Life Sciences (AIM:TILS) has announced the purchase of key assets from Shardna, a biobanking and genomics research company from Sardinia, an Italian island known for its large population of people living to an advanced age.

Tiziana, which is focused on targeted drugs to treat diseases in oncology and immunology, has also established an Italian subsidiary in Sardinia, LonGevia Genomics Srl.

The role of this subsidiary is to develop the acquired assets to identify novel drug targets and diagnostic applications, and the research has a particular benefit owing to Sardinia’s thriving older age group.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK